This is a working overview of thymosin alpha-1, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-20. Anything still debated is marked as such rather than presented as settled.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
A 2021 review found that people with FM had suicide ideation OR 9.12, suicide attempt OR 3.12, suicide risk OR 36.77 and suicide events HR 1.38, but commented that FM impact could not be separated from the effects of comorbidities and sleep deprivation. A 2020 review found that FM was associated with significantly higher risks for suicidal ideations, suicide attempts and death by suicide compared to the general population. A meta-analysis found that FM people were at a standardized mortality ratio of 1.95 (95% CI 0.97 to 3.92) due to accidents, and 1.66 (95% CI 1.15 to 2.38) due to infections. SMR due to cancer was a decreased rate of 0.82 (95% CI 0.69 to 0.97), perhaps because greater interaction with the health systems of people with FM leads to earlier cancer detection. The studies showed significant heterogeneity. A 2020 review found that many of the core clinical symptoms of FM were more strongly associated with suicidal ideation than with suicidal behaviours.
A countercurrent multiplication loop is a system where fluid flows in a loop so that the entrance and exit are at similar low concentration of a dissolved substance but at the far end of the loop there is a high concentration of that substance. A buffer liquid between the incoming and outgoing tubes receives the concentrated substance. The incoming and outgoing tubes do not touch each other. The system allows the buildup of a high concentration gradually, by allowing a natural buildup of concentration towards the tip inside the in-going tube, (for example using osmosis of water out of the input pipe and into the buffer fluid), and the use of many active transport pumps each pumping only against a very small gradient, during the exit from the loop, returning the concentration inside the output pipe to its original concentration. The incoming flow starting at a low concentration has a semipermeable membrane with water passing to the buffer liquid via osmosis at a small gradient. There is a gradual buildup of concentration inside the loop until the loop tip where it reaches its maximum. Theoretically a similar system could exist or be constructed for heat exchange. In the example shown in the image, water enters at 299 mg/L (NaCl / H2O). Water passes because of a small osmotic pressure to the buffer liquid in this example at 300 mg/L (NaCl / H2O). Further up the loop there is a continued flow of water out of the tube and into the buffer, gradually raising the concentration of NaCl in the tube until it reaches 1199 mg/L at the tip.
Sioux Nation of Indians and was involved in the Black Hills Land Claim John Lowenthal (1947), lawyer and documentary filmmaker known for his defense of Alger Hiss Norman Dorsen (1950), professor at the New York University School of Law and former president of the American Civil Liberties Union Robert O. Harris (1951), labor lawyer and chairman of the National Mediation Board Norman Marcus (1953), New York City Planning Commission general counsel and zoning expert Richard H. Stern (1953), attorney and law professor David Braun (1954), music industry lawyer, former president of PolyGram Records Alvin Hellerstein (1954), US federal judge Isaac Shapiro (1954), head of international practice at Skadden, Arps, Slate, Meagher & Flom, former president of Japan Society Clarence Benjamin Jones (1956), attorney and advisor to Martin Luther King Jr. Jerome H. Kern (1957), founder of Wachtell, Lipton, Rosen & Katz, former CEO of Playboy and Colorado Symphony Bernard Nussbaum (1958), White House counsel under Bill Clinton Ezra G. Levin (1959), lawyer, co-chair of international law firm Kramer Levin Naftalis & Frankel David G. Trager (1959), judge on the United States District Court for the Eastern District of New York Robert Abrams (1960), Bronx borough president and New York state attorney general Frank Tuerkheimer (1960), Watergate prosecutor and former U.S. attorney for the Western District of Wisconsin José A. Cabranes (1961), judge of the U.S. Court of Appeals; first Puerto Rican to sit in a U.S. District Court; current trustee of Columbia University Michael B.
Sources: en.wikipedia.org
== Outcomes == The primary measures of weight loss outcomes for endoscopic bariatric therapies include total body weight loss (percentage of pre-procedure weight lost by a certain time point) and excess weight loss (percentage of pre-procedure weight above ideal body weight that is lost by a certain time point). The Preservation and Incorporation of Valuable Endoscopic Innovation thresholds is an expert panel with gastroenterologists and surgeons from the American Society for Gastrointestinal Endoscopy and The American Society for Metabolic and Bariatric Surgery, and in 2015, this panel recommended that any new endoscopic therapy for weight loss should have an excess weight loss exceeding 25% and a serious adverse event rate less than 5%. Total body weight loss thresholds were not defined but are generally considered meaningful in novel endoscopic bariatric therapies if exceeding 5%. Multiple studies of ESG have shown that this therapy satisfies these criteria, as outlined below.
https://www.nobelprize.org/prizes/medicine/2023/press-release/ 2025: South African-born physicist and space scientist Michele Dougherty is appointed Astronomer Royal for the United Kingdom, becoming the first woman appointed to the role in its 350-year history. 2025: American biologist Mary E. Brunkow receives the Nobel Prize in Physiology or Medicine for her studies of the FOXP3 gene, which was significant to future studies of peripheral immune tolerance. She shared this award with immunologists Fred Ramsdell and Shimon Sakaguchi. 2026: Kazakhstan launches its first all female Space Isolation Experiment, SANA-1, at the National Space Center.
The Workers Party of Bangladesh (reconstituted) was a political party in Bangladesh. Haider Akbar Khan Rano was the convenor of the party. Rano had led a group of dissident leaders of the Workers Party of Bangladesh, who had broken away from WPB in connection with the December 2008 parliamentary election. Rano's group, which formed the WPB(reconstituted) opposed the alliance between the Workers Party and the Awami League and the participation of WPB candidates in the election on the Awami League election symbol. In September 2009 Abdul Matin, a hero of the Language movement, joined the party. Matin was included in the Central Committee of the party. Afterwards he joined to the party United Communist League of Bangladesh. On 26 February 2010, the Workers Party of Bangladesh (reconstituted) merged into the Communist Party of Bangladesh. Haider Akbar Khan Rano was included in the presidium of CPB and Mohamed Habibur Rahman and Shahrier Mohammad Firoj were appointed Central Committee members of CPB.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.